Anika Therapeutics (ANIK) Asset Writedowns and Impairment (2010 - 2026)

Anika Therapeutics (ANIK) has reported Asset Writedowns and Impairment for 17 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Asset Writedowns and Impairment fell 48.74% year-over-year to $1.5 million in Q2 2026; TTM through Jun 2026 was $4.6 million, a 82.19% decrease from a year earlier, with the FY2025 full-year figure at $5.8 million, down 86.98% from the prior year.
• Asset Writedowns and Impairment was $1.5 million for Q2 2026 at Anika Therapeutics, up from $1.0 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $59.6 million in Q4 2023 and troughed at $89000.0 in Q2 2022.
• A 5-year average of $5.8 million and a median of $1.1 million in 2025 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment soared 3559.89% in 2023 and plunged 95.43% in 2025, its largest moves.
• Over 5 years, Asset Writedowns and Impairment stood at $1.6 million in 2022, then soared by 3559.89% to $59.6 million in 2023, then slumped by 68.73% to $18.6 million in 2024, then sank by 95.43% to $852000.0 in 2025, then surged by 81.1% to $1.5 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $1.5 million (Q2 2026), $1.0 million (Q1 2026), and $852000.0 (Q4 2025), per Business Quant data.